
|Videos|June 19, 2023
CARD Trial: Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
Author(s)Alicia K. Morgans, MD, MPH
Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to Givastomig for Frontline HER2-Negative Metastatic Gastric Cancer
2
EHA 2026 Multiple Myeloma Highlights Have Worldwide Impact
3
Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma
4
Tec/Dara Offers a Path Forward in Relapsed Myeloma When CAR T Is Not an Option
5






































